JP2021530251A5 - - Google Patents
Info
- Publication number
- JP2021530251A5 JP2021530251A5 JP2021526401A JP2021526401A JP2021530251A5 JP 2021530251 A5 JP2021530251 A5 JP 2021530251A5 JP 2021526401 A JP2021526401 A JP 2021526401A JP 2021526401 A JP2021526401 A JP 2021526401A JP 2021530251 A5 JP2021530251 A5 JP 2021530251A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103530A JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700174P | 2018-07-18 | 2018-07-18 | |
| US62/700,174 | 2018-07-18 | ||
| US201962792798P | 2019-01-15 | 2019-01-15 | |
| US62/792,798 | 2019-01-15 | ||
| PCT/US2019/042493 WO2020018852A2 (en) | 2018-07-18 | 2019-07-18 | Novel antibodies and methods for making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103530A Division JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530251A JP2021530251A (ja) | 2021-11-11 |
| JP2021530251A5 true JP2021530251A5 (https=) | 2023-03-10 |
| JP7513605B2 JP7513605B2 (ja) | 2024-07-09 |
Family
ID=69165232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526401A Active JP7513605B2 (ja) | 2018-07-18 | 2019-07-18 | 新規な抗体ならびにそれを調製および使用するための方法 |
| JP2024103530A Pending JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103530A Pending JP2024133536A (ja) | 2018-07-18 | 2024-06-27 | 新規な抗体ならびにそれを調製および使用するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11505618B2 (https=) |
| EP (1) | EP3824096A4 (https=) |
| JP (2) | JP7513605B2 (https=) |
| CN (1) | CN112513093B (https=) |
| WO (1) | WO2020018852A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7513605B2 (ja) * | 2018-07-18 | 2024-07-09 | アスクジーン・ファーマ・インコーポレイテッド | 新規な抗体ならびにそれを調製および使用するための方法 |
| SG11202108398YA (en) | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
| AU2021220887B2 (en) * | 2020-02-10 | 2024-11-21 | Shanghai Escugen Biotechnology Co., Ltd. | CLDN18.2 antibody and use thereof |
| CN115715202B (zh) * | 2020-05-15 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 抗体药物缀合物及其制备方法和用途 |
| CN111808194B (zh) * | 2020-07-13 | 2021-04-20 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| CN111704669B (zh) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种用于治疗晚期胃癌的抗cldn18全人源化抗体 |
| JP7726978B2 (ja) * | 2020-07-13 | 2025-08-20 | 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 | 抗ｃｌｄｎ－１８．２抗体及びその用途 |
| WO2022068854A1 (en) * | 2020-09-30 | 2022-04-07 | Nanjing GenScript Biotech Co., Ltd. | Antibodies targeting human claudin 18.2 and uses thereof |
| CN114504642B (zh) * | 2020-11-17 | 2026-03-27 | 江苏奥赛康生物医药有限公司 | 一种含抗cldn18.2抗体的液体药物组合物 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| TW202241519A (zh) | 2020-12-23 | 2022-11-01 | 捷克商舒迪安生物技術公司 | 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物 |
| CN114805571B (zh) * | 2021-01-28 | 2023-08-25 | 广西鹭港生物医药科技有限公司 | 抗cldn18.2抗体及其应用 |
| WO2022206975A1 (zh) * | 2021-04-02 | 2022-10-06 | 原启生物科技(上海)有限责任公司 | Cldn18.2抗原结合蛋白及其用途 |
| CN115611983A (zh) * | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| CN121464158A (zh) * | 2023-05-22 | 2026-02-03 | 西雅图免疫公司 | 抗Claudin18.2抗体及其制备和使用方法 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025082356A1 (zh) * | 2023-10-16 | 2025-04-24 | 江苏奥赛康生物医药有限公司 | Cldn18_2抗体与化学治疗药物的组合及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026050214A1 (en) | 2024-08-27 | 2026-03-05 | Bolt Biotherapeutics, Inc. | Anti-claudin, tlr agonist immunoconjugates and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2018026742A1 (en) * | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| JP7513605B2 (ja) * | 2018-07-18 | 2024-07-09 | アスクジーン・ファーマ・インコーポレイテッド | 新規な抗体ならびにそれを調製および使用するための方法 |
-
2019
- 2019-07-18 JP JP2021526401A patent/JP7513605B2/ja active Active
- 2019-07-18 CN CN201980029283.3A patent/CN112513093B/zh active Active
- 2019-07-18 US US16/516,223 patent/US11505618B2/en active Active
- 2019-07-18 EP EP19838910.8A patent/EP3824096A4/en active Pending
- 2019-07-18 WO PCT/US2019/042493 patent/WO2020018852A2/en not_active Ceased
-
2022
- 2022-11-21 US US17/991,775 patent/US12312413B2/en active Active
-
2024
- 2024-06-27 JP JP2024103530A patent/JP2024133536A/ja active Pending